Learn how nurse-led care coordination supports members right after their specialty therapy starts. Learn how the compassionate experts at Prime help members understand their treatment, set expectations and get support when it’s needed.

Tune in to hear how nurse-led coordination is reducing costs and improving care for the better, including:

• Fewer early missteps through clear patient education
• Better member experience through personalized support
• Reduced urgent care and ER visits through early symptom management

Chapters

02:22 - Introduction to care management

05:35 - Care management availability

06:45 - Patient impact of care management

10:17 - Common conditions that care management teams help with

11:52 - Caregiver assistance

14:23 - Better patient outcomes, means stronger health systems

17:33 - The "why" behind care management is about compassion

18:41 - Closing

Recorded live in Nashville at AMCP Annual 2026, our latest Pharmacy Friends shares takeaways on how real-world medical and pharmacy data, pharmacist-led outreach, and benefit integration are shaping payer decision-making.

00:45 - Why real-time evidence matters

09:37 - High-touch pharmacist-to-prescriber outreach helps deliver hard-dollar savings.

23:51 – Rare disease insight and reinforcing the need for individualized management and payer case-management opportunities.

36:02 -- Why site of care in CAR-T and BiTE therapy matter

43:20 – Why mental health parity compliance in government programs matter now

52:55-- Integration signal by highlighting the value of coordinated care.

These insights are foundational to how Prime delivers value to health care payers. Using evidence-driven expertise on how therapies are used, where gaps exist and which patients benefit most from additional support, Prime translates research into smarter clinical strategies and high-touch support for patients.

Dive into the real stories, smart insights, and everyday moments that bring the world of pharmacy and everyday life together—one authentic conversation at a time.

Early-onset cancers are rising—and they’re forcing people to rethink cancer, screenings and care models.

What if cancer care strategy needs to start earlier—and last longer? This Pharmacy Friends conversation breaks down the rise in early-onset cancers and the practical implications for prevention, benefit design, and affordability.

00:00 Intro

02:30 Basics of cancer in younger people

07:52 Early onset cancer impact on health plans

11:14 Patient challenges and decision making

15:23 Impact on affordability

22:00 Importance of medical and pharmacy benefit integration

27:38 New ways of offering cancer care

30:41 Role that AI can play in patient care

33:26 Should health care adapt for best clinical outcomes

34:50 Being an advocate for the patient

38:49 Closing

Content in this podcast is for informational or educational purposes only. The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

Discover how Prime brings together industry recognized accreditation frameworks—like URAC, ISO, and NCQA—to create a unified, reliable approach to patient safety and operational excellence. In this episode, we break down how quality standards become everyday practice through embedded processes, continuous improvement, internal audits, and real world examples that demonstrate measurable impact for clients, members, and partners.

00:20: Intro

03:12: Importance of quality operations

15:50: Pharmacy accreditations on the frontline

22:15: Preparing for an emergency

23:25: Being a trusted partner

28:56: What's next in the quality universe?

31:52: New & emerging accreditations to watch

33:50: Closing

During this episode of Pharmacy Friends you’ll hear about the rapidly evolving world of cell and gene therapy, highlighting its promise, complexity, and growing impact across the health care ecosystem. Learn about the foundational definitions, emerging clinical innovations, and the expanding pipeline of therapies expected to reach the market in the coming years. It also examines regulatory developments, forecasting approaches, financial considerations, and the human elements that shape patient and provider decision‑making. Through expert insights and real‑world examples, the conversation illustrates how Prime is helping stakeholders navigate this dynamic landscape while preparing for the transformative potential of next‑generation therapies.

Listen to the latest episode of the “Pharmacy Friends” podcast

Read the latest Cell & Gene Pipeline Outlook

Learn more about how Prime manages cell and gene therapies

In this episode:

03:46 What is Cell & Gene Therapy?

04:34 What is the Cell & Gene Therapy Pipeline?

08:13 Why pay attention to cell & gene therapies?

12:45: Collaboration with all stakeholders is important to get the right therapies to patients

20:35: Digging in new therapies that are on the horizon

22:56: Importance of the FDA commissioner's national priority voucher

25:52: What to consider when these therapies are an option

28:40: Is cost a barrier to these therapies?

31:41: 2026 cell and gene therapy outlook

36:18: Closing - books and fishing

Learn about the FDA’s new expedited approval process for oral GLP-1 medications—a breakthrough that could transform obesity care. Host Maryam Tabatabai and Carole Kerzic talk about these once-daily pills, and their potential for the similar benefits as injectables without needles or refrigeration. With potential approval coming soon, oral GLP-1s could expand access, impact adherence, and help reshape the weight-loss market. Staying informed is critical: these drugs not only aid weight management but also improve cardiometabolic health. Tune in to learn why understanding the latest developments matters for payers, clinicians, patients, and policymakers.

GLP-1 Pipeline Update: November 2025

00:00 Overview

00:49 Introduction to oral GLP-1s

02:43 Evidence from clinical trials

10:28 Big picture if FDA approves oral GLP-1s

14:08 Must know: Non-peptide vs peptide

15:45 More patient friendly formulation?

17:38 Market & timing for oral GLP-s

Content in this podcast is for informational or educational purposes only. The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

Research is more than just finding interesting stats. It's about finding better ways to deliver savings, simplicity, and support. In this episode, you’ll hear from managed care pharmacy researchers who are doing just that, delivering data driven insights to drive affordability and access in health care.

Pat Gleason, PharmD, BCPS, FCCP, FAMCP, assistant vice president of health outcomes; Nick Friedlander, PharmD, clinical program pharmacist; and Simone Ndujiuba, PharmD, BCOP, clinical oncology pharmacist senior principal; and host Alex Cook, senior public relations manager, discuss how Prime’s research helps address affordability and accessibility issues and guides health care providers and peers toward clarity on treatment for complex health conditions.

Research topics covered:

• Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes
• Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes — This study earned a platinum award from AMCP.
• Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program— This study earned a gold award from AMCP.
• Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention — This study earned a gold award from AMCP.
• Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma

-------------------------

Content in this podcast is for informational or educational purposes only.

The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

Unpacking signals emerging from claims, medical records, and patient-reported outcomes to shape the next wave of GLP-1 strategy.

Listen in and hear from industry experts who explore the evolving story of GLP-1 medications. Host Maryam Tabatabai and her guests discuss three years of GLP1 research data and examine why data is essential for clinical decision support, population health, and predictive analytics. Pat Gleason, David Lassen and Sarah Taylor address why stakeholders need to think about tackling the rising costs of weight management and GLP-1 access and why they believe sharing real-world insights is important so next generation pharmacy solutions can be built. Tune in as we reveal what the latest data shows and what’s next for GLP-1 research and innovation.

Learn more about developing a holistic GLP-1 strategy
Get the latest GLP-1 insights
Year-3 adherence and persistence data
The Skinny on GLP-1s: Part 1 | Part 2